BIB - ProShares Ultra Nasdaq Biotechnology
Stock Price: $87.12 USD
-1.06 (-1.20%)
Updated Apr 22, 2021 10:24 AM EDT - Market open
| Assets | $203.60M |
| NAV | $84.83 |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Beta (5Y) | 1.99 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Sep 21, 2010 |
| 1-Year Return | - |
| Trading Day | April 22 |
| Last Price | $87.12 |
| Previous Close | $88.18 |
| Change ($) | -1.06 |
| Change (%) | -1.20% |
| Day's Open | 87.50 |
| Day's Range | 86.08 - 87.90 |
| Day's Volume | 21,843 |
| 52-Week Range | 56.19 - 113.06 |
Fund Description
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
| Asset Class Equity | Sector Biotech |
| Region North America | Inception Date Apr 8, 2010 |
| Exchange NASDAQ | Ticker Symbol BIB |
| Index Tracked NASDAQ Biotechnology Index | |
Top 10 Holdings
132.35% of assets| Name | Symbol | Weight |
|---|---|---|
| Nasdaq Biotechnology Index Swap Societe Generale | 603698.SS | 26.92% |
| Nasdaq Biotechnology Index Swap Ubs Ag | 603698.SS | 25.08% |
| Cash | n/a | 16.22% |
| Nasdaq Biotechnology Index Swap Citibank Na | 603698.SS | 12.91% |
| Ishares Biotech (Ibb) Swap Goldman Sachs International | 603698.SS | 11.73% |
| Nasdaq Biotechnology Index Swap Bank Of America Na | 603698.SS | 10.88% |
| Nasdaq Biotechnology Index Swap Credit Suisse International | 603698.SS | 8.83% |
| Amgen | AMGN | 7.74% |
| Nasdaq Biotechnology Index Swap Goldman Sachs International | 603698.SS | 6.30% |
| Gilead Sciences | GILD | 5.75% |
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Last week witnessed a tug-of-war between bulls and bears.